Isolation, Characterization and Probiotic Properties of Levilactobacillus brevis FS1 from Fermented Food and Its...

Probiotic provide a different level of health benefits to human and animals. Many studies confirmed that probiotic supplement inhibits obesity, but these treatments are still restricted. As a probiotic Levilactobacillus brevis FS1 has been considered a potent bio-therapeutic agent to control several illnesses. In the present study, we examined theprobiotic potential of L. brevis FS1 and its cell free metabolites effect on the fat deposition and differentiation of 3T3-L1 adipocytes. The data suggested that L. brevis FS1 showed significant survival ability in harsh condition of gastrointestinal tract and had hydrophobicity and auto aggregation properties. Furthermore, cell free metabolites from L. brevis FS1 (CMLB) treatment reduced fat deposition and the genes related to adipogenesis and lipogenesis such as C/EBP-β (CCAAT/ enhancer-binding protein- β), PPAR-γ (Peroxisome proliferator activated receptor- γ), acetyl CoA carboxylase (ACC), Fatty acid synthase (FAS), adipocyte binding protein (aP2), Serum regulatory element binding protein-1 (SREBP-1) and increased insulin sensitizing protein adiponectin expression compared to control cells. The competitive study between CMLB and rosiglitazone (RGZ) confirmed that CMLB treatment reduced fat deposition and PPAR γ expression induced by PPAR γ agonist RGZ. It concludes that L. brevis FS1 may be considered as potent probiotic could be used for treatment of obesity and its associated diseases by downregulating key adipogenic and lipogenic markers.